News
Press Releases
-
Oct 25, 2025
SGB-9768 (C3 siRNA) Clinical Data to be Reported at ASN Kidney Week 2025
-
Oct 21, 2025
SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768, an Experimental RNAi Medicine Targeting C3 mRNA
-
Sep 19, 2025
SanegeneBio Receives NMPA Approval to Initiate Clinical Trial of SGB-3383 for Complement-Mediated Blood Disorders
-
Jun 30, 2025
SanegeneBio Announces First Patient Dosed in Phase 1 Trial of SGB-3383
-
May 20, 2025
SanegeneBio Receives NMPA Approval to Initiate Clinical Trial of siRNA Candidate SGB-3383 for Complement-Mediated Kidney Diseases
-
Mar 7, 2025
SanegeneBio Initiates Phase 2 Trial of an Experimental RNAi-Based Medicine SGB-9768 Targeting C3 mRNA
-
Dec 11, 2024
SanegeneBio Announced First-in-Human Phase 1 Clinical Data for SGB-9768 at the 8th Complement-Based Drug Development Summit
-
Aug 6, 2024
SanegeneBio Announces FSD in Phase 1 Clinical Trial of SGB-9768
-
Aug 2, 2024
SanegeneBio and Innovent Announce FPD in a Phase 1 Clinical Trial of SGB-3908
-
Jun 25, 2024
SGB-9768 (C3 siRNA) Receives Clinical Trial Approval in China for the Treatment of Complement-Mediated Diseases